LM-302 not checked

LaNova Medicines

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle”In the company’s words, NCT06351020 on ClinicalTrials.gov
Tested for
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Malignant Neoplasms of Digestive Organs
Main trialPhase 3
“This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy”In the company’s words, NCT06351020 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 10 Nov 2026 LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
Phase 2Recruiting 6 Aug 2031 A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Phase 1/2Completed 14 Nov 2023 Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Phase 1/2Completed 10 Jan 2025 Study of LM-302 in Patients With Advance Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LM-302

Following is part of Solo: you see every change to LM-302 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in